Recent advances in management of bladder overactivity

F1000 Medicine Reports

Volumn 2, Issue 1, 2010, Pages

  Smith, Ariana L ^a   Wein, Alan J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETANILIDE; BETA 3 ADRENERGIC RECEPTOR; BOTULINUM TOXIN A; FESOTERODINE; OXYBUTYNIN; PHOSPHODIESTERASE; PLACEBO; SILDENAFIL; TADALAFIL; TOLTERODINE; TROSPIUM CHLORIDE; UNCLASSIFIED DRUG; VARDENAFIL; YM 178;

CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; CONSTIPATION; DETRUSOR MUSCLE; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HEADACHE; HEALTH CARE COST; HUMAN; LUMBOSACRAL PLEXUS; NEUROMODULATION; OUTCOME ASSESSMENT; OVERACTIVE BLADDER; PATHOPHYSIOLOGY; QUALITY OF LIFE; REVIEW; TIBIAL NERVE; TRANSCUTANEOUS NERVE STIMULATION; XEROSTOMIA;

EID: 77955066847     PISSN: None     EISSN: 17575931     Source Type: Journal    
DOI: 10.3410/M2-9     Document Type: Review

References (43)

1. Cartwright R, Cardozo L: Transdermal oxybutynin: sticking to the facts. Eur Urol 2007, 51:907-14.
2. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A; Standardisation Sub-Committee of the International Continence Society: The standardisation of terminology of lower urinary tract function: report from the standarisation sub-committee of the International Continence Society. Neurourol Urodyn 2002, 21:167-78.
3. Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D: The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008, 54:543-62.
4. Andersson KE: New pharmacologic targets for the treatment of the overactive bladder: an update. Urology 2004, 63(Suppl 3A):32-41.
5. Staskin DR, Dmochowski RR, Sand PK, Macdiarmid SA, Caramelli KE, Thomas H, Hoel G: Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study. J Urol 2009, 181:1764-72.
6. Chapple C, Van Kerrebroeck P, Tubaro A, Haag-Molkenteller C, Forst HT, Massow U, Wang J, Brodsky M: Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol 2007, 52:1204-12.
7. Michel MC: Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother 2008, 9:1787-96.
8. Khullar V, Rovner ES, Dmochowski R, Nitti V, Wang J, Guan Z: Fesoterodine dose response in subjects with overactive bladder syndrome. Urology 2008, 71:839-43.
9. Staskin D, Sand P, Zinner N, Dmochowski R; Trospium Study Group: Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. J Urol 2007, 178(3 Pt 1):978-83.
10. Dmochowski RR, Sand PK, Zinner NR, Staskin DR: Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. Urology 2008, 71:449-54.
11. MacDiarmid S, Sandage BW Jr, Malhotra BK: The effects of reformulation: improved therapeutic index. Curr Urol Rep 2008, 9:465-71.
12. Nomiya M, Yamaguchi O: A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. J Urol 2003, 170(2 Pt 1):649-53.
13. Michel MC, Vrydag W: Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 2006, 147(Suppl 2):S88-119.
14. Woods M, Carson N, Norton NW, Sheldon JH, Argentieri TM: Efficacy of the beta3-adrenergic receptor agonist CL-316243 on experimental bladder hyperreflexia and detrusor instability in the rat. J Urol 2001, 166:1142-7.
15. Wein AJ, Levin RM, Barrett DM: Voiding function: relevant anatomy, physiology, and pharmacology. In Adult and Pediatric Urology. Edited by Duckett JW, Howards ST, Grayhack JT, Gillenwater JY. St. Louis, MO: Mosby; 1991:933-99.16.
16. Chapple CR, Yamaguchi O, Ridder A, Liehne J, Carl S, Mattiasson A, Aramburu MAL, Lucas M, Everaert K: Clinical proof of concept study (Blossom) shows novel b3 andrenoceptor agonist YM178 is effective and well tolerated in the treatment of symptoms of overactive bladder. Eur Urol Suppl 2007, 7:239. Abstract 674.
17. Sairam K, Kulinskaya E, McNicholas TA, Boustead GB, Hanbury DC: Sildenafil influences lower urinary tract symptoms. BJU Int 2002, 90:836-9.
18. Andersson KE: Pathways for relaxation of detrusor smooth muscle. Adv Exp Med Bio 1999, 462:241-52.
19. McVary KT, Monnig W, Camps JL Jr, Young JM, Tseng LJ, van den Ende G: Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 2007, 177:1071-7.
20. Datta SN, Kavia RB, Gonzales G, Fowler CJ: Results of double-blind placebo-controlled crossover study of sildenafil citrate (Viagra) in women suffering from obstructed voiding or retention associated with the primary disorder of sphincter relaxation (Fowler's Syndrome). Eur Urol 2007, 51:495-7.
21. McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, Esler A, Sides GD, Denes BS: Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007, 177:1401-7.
22. Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E: A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2008, 53:1236-44.
23. Truss MC, Stief CG, Uckert S, Becker AJ, Wefer J, Schultheiss D, Jonas U: Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: from bench to bedside. World J Urol 2001, 19:344-50.
24. Schurch B, Schmid DM, Stöhrer M: Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med 2000, 342:665.
25. Dmochowski R, Sand PK: Botulinum toxin A in the overactive bladder: current status and future directions. BJU Int 2007, 99:247-62.
26. Kalsi V, Gonzales G, Popat R, Apostolidis A, Elneil S, Dasgupta P, Fowler CJ: Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann Neurol 2007, 62:452-7.
27. Reitz A, Denys P, Fermanian C, Schurch B, Comperat E, Chartier-Kastler E: Do repeat intradetrusor botulinum toxin type a injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity. Eur Urol 2007, 52:1729-35.
28. Sahai A, Khan MS, Dasgupta P: Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol 2007, 177:2231-6.
29. Brubaker L, Richter HE, Visco A, Mahajan S, Nygaard I, Braun TM, Barber MD, Menefee S, Schaffer J, Weber AM, Wei J; Pelvic Floor Disorders Network: Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 2008, 180:217-22.
30. Schmid D, Sauermann P, Werner M, Schuessler B, Blick N, Muentener M, Strebel RT, Perucchini D, Scheiner D, Schaer G, John H, Reitz A, Hauri D, Schurch B: Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 2006, 176:177-85.
31. Fowler CJ, Swinn MJ, Goodwin RJ, Oliver S, Craggs M: Studies of the latency of pelvic floor contraction during peripheral nerve evaluation show that the muscle response is reflexly mediated. J Urol 2000, 163:881-3.
32. Kessler TM, Fowler CJ: Sacral neuromodulation for urinary retention. Nat Clin Pract Urol 2008, 5:657-66.
33. Wallace PA, Lane FL, Noblett KL: Sacral nerve neuromodulation in patients with underlying neurologic disease. Am J Obstet Gynecol 2007, 197:96.e1-5.
34. Lombardi G, Del Popolo G: Clinical outcome of sacral neuromodulation in incomplete spinal cord injured patients suffering from neurogenic lower urinary tract symptoms. Spinal Cord 2009, 47:486-91.
35. Peters KM, Macdiarmid SA, Wooldridge LS, Leong FC, Shobeiri SA, Rovner ES, Siegel SW, Tate SB, Jarnagin BK, Rosenblatt PL, Feagins BA: Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol 2009, 182:1055-61.
36. Govier FE, Litwiller S, Nitti V, Kreder KJ Jr, Rosenblatt P: Percutaneous afferent neuromodulation for the refractory overactive bladder: results of a multicenter study. J Urol 2001, 165:1193.
37. Spinelli M, Malaguti S, Giardiello G, Lazzeri M, Tarantola J, Van Den Hombergh U: A new minimally invasive procedure for pudendal nerve stimulation to treat neurogenic bladder: description of the method and preliminary data. Neurourol Urodyn 2005, 24:305-9.
38. Peters KM, Killinger KA, Boguslawski BM, Boura JA: Chronic pudendal neuromodulation: expanding available treatment options for refractory urologic symptoms. Neurourol Urodyn 2009, [Epub ahead of print].
39. Peters KM, Feber KM, Bennett RC: Sacral versus pudendal nerve stimulation for voiding dysfunction: a prospective, single-blinded, randomized, crossover trial. Neurourol Urodyn 2005, 24:643-7.
40. Andersson KE, Wein AJ: Pharmacologic management of storage and emptying failure In Campbell-Walsh Urology. Edited by Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA. Philadelphia: Saunders; 2007:2091-123.
41. Andersson KE, Chapple CR, Cardozo L, Cruz F, Hashim H, Michel MC, Tannenbaum C, Wein AJ: Pharmacological treatment of urinary incontinence. In Incontinence. Edited by Abrams P, Cardozo L, Khoury S, Wein AJ. Paris: Health Publication Ltd; 2009:631-99.
42. Malhotra B, Gandelman K, Sachse R, Wood N, Michel MC: The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine. Curr Med Chem 2009, 16:4481-9.
43. Todorova A, Vonderheid-Guth B, Dimpfel W: Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol 2001, 41:636-44.